We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $32 · 4 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility - AD HOC NEWS
Precision BioSciences stock (US74019P1084): shares edge higher amid biotech volatility AD HOC NEWS
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award - Stock Titan
Executive at Precision BioSciences (DTIL) receives 57,389 RSU compensation award Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel - Stock Titan
Precision BioSciences (DTIL) awards 107,604 RSUs to General Counsel Stock Titan
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity - Stock Titan
[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units - Stock Titan
Precision BioSciences (NASDAQ: DTIL) CEO receives 573,888 restricted stock units Stock Titan
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL) The Globe and Mail
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.6 | — | — | $1.75M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-2.21 | — | — | $29K | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $3.78 | — | — | $68.06M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $6.81 | — | — | $67.48M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 05. 21. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 03. 28. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 03. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 02. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 01. 10. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 307,790 | $1.69B | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 139,531 | $580.45M | 0.00% | — | New position |
| 3 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 35,593 | $195.76M | 0.00% | — | New position |
| 4 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 29,607 | $123.17M | 0.00% | — | New position |